-
- Chris Moran
- Stroke and Ageing Research Group, Department of Medicine, Southern Clinical School, Monash University, Melbourne, Australia
-
- Thanh G. Phan
- Stroke and Ageing Research Group, Department of Medicine, Southern Clinical School, Monash University, Melbourne, Australia
-
- Jian Chen
- Stroke and Ageing Research Group, Department of Medicine, Southern Clinical School, Monash University, Melbourne, Australia
-
- Leigh Blizzard
- Menzies Research Institute Tasmania, Hobart, Tasmania, Australia
-
- Richard Beare
- Stroke and Ageing Research Group, Department of Medicine, Southern Clinical School, Monash University, Melbourne, Australia
-
- Alison Venn
- Menzies Research Institute Tasmania, Hobart, Tasmania, Australia
-
- Gerald Münch
- Department of Pharmacology and Molecular Medicine Research Group, School of Medicine, University of Western Sydney, Campbelltown, Australia
-
- Amanda G. Wood
- Critical Care and Neurosciences, Murdoch Children’s Research Institute, Melbourne, Australia
-
- Josephine Forbes
- Baker-IDI Heart and Diabetes Institute, Monash University, Melbourne, Australia
-
- Timothy M. Greenaway
- Royal Hobart Hospital, Hobart, Tasmania, Australia
-
- Susan Pearson
- Menzies Research Institute Tasmania, Hobart, Tasmania, Australia
-
- Velandai Srikanth
- Stroke and Ageing Research Group, Department of Medicine, Southern Clinical School, Monash University, Melbourne, Australia
説明
<jats:sec> <jats:title>OBJECTIVE</jats:title> <jats:p>Type 2 diabetes (T2DM) is associated with brain atrophy and cerebrovascular disease. We aimed to define the regional distribution of brain atrophy in T2DM and to examine whether atrophy or cerebrovascular lesions are feasible links between T2DM and cognitive function.</jats:p> </jats:sec> <jats:sec> <jats:title>RESEARCH DESIGN AND METHODS</jats:title> <jats:p>This cross-sectional study used magnetic resonance imaging (MRI) scans and cognitive tests in 350 participants with T2DM and 363 participants without T2DM. With voxel-based morphometry, we studied the regional distribution of atrophy in T2DM. We measured cerebrovascular lesions (infarcts, microbleeds, and white matter hyperintensity [WMH] volume) and atrophy (gray matter, white matter, and hippocampal volumes) while blinded to T2DM status. With use of multivariable regression, we examined for mediation or effect modification of the association between T2DM and cognitive measures by MRI measures.</jats:p> </jats:sec> <jats:sec> <jats:title>RESULTS</jats:title> <jats:p>T2DM was associated with more cerebral infarcts and lower total gray, white, and hippocampal volumes (all P < 0.05) but not with microbleeds or WMH. T2DM-related gray matter loss was distributed mainly in medial temporal, anterior cingulate, and medial frontal lobes, and white matter loss was distributed in frontal and temporal regions. T2DM was associated with poorer visuospatial construction, planning, visual memory, and speed (P ≤ 0.05) independent of age, sex, education, and vascular risk factors. The strength of these associations was attenuated by almost one-half when adjusted for hippocampal and total gray volumes but was unchanged by adjustment for cerebrovascular lesions or white matter volume.</jats:p> </jats:sec> <jats:sec> <jats:title>CONCLUSIONS</jats:title> <jats:p>Cortical atrophy in T2DM resembles patterns seen in preclinical Alzheimer disease. Neurodegeneration rather than cerebrovascular lesions may play a key role in T2DM-related cognitive impairment.</jats:p> </jats:sec>
収録刊行物
-
- Diabetes Care
-
Diabetes Care 36 (12), 4036-4042, 2013-11-13
American Diabetes Association